What is Sarepta Therapeutics, Inc.'s deferred revenue?

Sarepta Therapeutics, Inc. (SRPT) reported deferred revenue of -$274.92M in Q1 2026.

How has Sarepta Therapeutics, Inc.'s deferred revenue changed year-over-year?

Sarepta Therapeutics, Inc.'s deferred revenue decreased by 221.9% year-over-year, from -$85.4M to -$274.92M.

What is the long-term trend for Sarepta Therapeutics, Inc.'s deferred revenue?

Over 3 years (2021 to 2025), Sarepta Therapeutics, Inc.'s deferred revenue has grown at a -6.9% compound annual growth rate (CAGR), from -$89.24M to $72.05M.

Sarepta Therapeutics, Inc. SRPT Deferred Revenue

Deferred Revenue at other companies

Stoke Therapeutics, Inc.STOK

——

BridgeBio PharmaBBIO

——

Relay Therapeutics, Inc.RLAY

——

Other financials

Income statement

See full

Revenue$730.8M-1.9%

Operating income-$300.4M-961%

Net income$331.0M+174%

EPS (diluted)-$4.60-1,343%

Balance sheet

See full

Cash & equivalents$464.5M+92.8%

Total debt$198.5M-3.4%

Total equity$1.5B+31.7%

Total assets$3.2B-8.3%

Cash flow

See full

Operating cash flow-$202.7M+65.3%

CapEx$2.1M-95.2%

Free cash flow-$204.8M+67.3%

Valuation

See full

Market cap$1.76B-63.1%

Profitability

See full

Operating margin-50.8%-1.6pp

Net margin4.6%+2.4pp

FCF margin-28.7%-9.2pp

Returns & leverage

See full

Return on equity-23.6%-28.5pp

Debt / equity0.1×0.0×

Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s deferred revenue?: Sarepta Therapeutics, Inc. (SRPT) reported deferred revenue of -$274.92M in Q1 2026.
How has Sarepta Therapeutics, Inc.'s deferred revenue changed year-over-year?: Sarepta Therapeutics, Inc.'s deferred revenue decreased by 221.9% year-over-year, from -$85.4M to -$274.92M.
What is the long-term trend for Sarepta Therapeutics, Inc.'s deferred revenue?: Over 3 years (2021 to 2025), Sarepta Therapeutics, Inc.'s deferred revenue has grown at a -6.9% compound annual growth rate (CAGR), from -$89.24M to $72.05M.